» Articles » PMID: 18165638

Increased Uptake of BRCA1/2 Genetic Testing Among African American Women with a Recent Diagnosis of Breast Cancer

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2008 Jan 1
PMID 18165638
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Studies suggest that African American women are less likely to pursue BRCA1/2 genetic testing than white women. However, such studies are often confounded by unequal access to care.

Methods: Data from 132 African American and 636 white women, obtained from a clinical database at the University of North Carolina (Chapel Hill, NC) between 1998 and 2005, were analyzed to assess BRCA1/2 genetic testing uptake. Importantly, the clinical setting minimized barriers of both cost and access. Race and time of new breast cancer diagnosis (recent v > 1 year before genetic evaluation) were assessed for association with BRCA1/2 testing uptake using multivariable logistic regression models.

Results: Both race (P = .0082) and a recent diagnosis of breast cancer (P = .014) were independently associated with testing uptake. African American women had a lower estimated odds of pursuing testing than white women (odds ratio [OR], 0.54; 95%CI, 0.34 to 0.85), and women with a recent diagnosis had a higher OR than those with a remote diagnosis (OR, 1.58; 95% CI, 1.10 to 2.29). In a race-stratified analysis, there was no statistical evidence for association between recent status and testing uptake in the larger white stratum (OR, 1.38, P = .13) while there was for the smaller African American sample (OR, 2.77, P = .018). The test of interaction between race and remote status was not significant (P = .15).

Conclusion: African American race was associated with an overall decreased uptake of BRCA1/2 genetic testing, even when barriers of ascertainment and cost were minimized. However, among African American women, a recent diagnosis of breast cancer was associated with substantially increased uptake of testing.

Citing Articles

Disparities in Genetic Testing for Inborn Errors of Immunity.

Gilbert K, McLaughlin H, Farmer J, Ong M J Allergy Clin Immunol Pract. 2024; 13(2):388-395.e3.

PMID: 39579980 PMC: 11807750. DOI: 10.1016/j.jaip.2024.11.011.


Breast Cancer Germline Genetic Counseling and Testing for Populations of African Heritage Globally: A Scoping Review on Research, Practice, and Bioethical Considerations.

Iwai Y, Toumbou K, Zuze T, Morgan J, Simwinga L, Wright S JCO Glob Oncol. 2023; 9:e2300154.

PMID: 37944088 PMC: 10645409. DOI: 10.1200/GO.23.00154.


The Role of Race and Insurance Status in Access to Genetic Counseling and Testing Among High-Risk Breast Cancer Patients.

Choi J, Fikre T, Fischman A, Buck A, Ko N Oncologist. 2022; 27(10):832-838.

PMID: 36124631 PMC: 9526492. DOI: 10.1093/oncolo/oyac132.


Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.

Henderson V, Madrigal J, Kendall L, Parekh P, Newsome J, Chukwudozie I BMC Health Serv Res. 2022; 22(1):826.

PMID: 35752812 PMC: 9233847. DOI: 10.1186/s12913-022-08193-x.


Healthcare Predictors of Information Dissemination About Genetic Risks.

Henderson V, Strayhorn S, Bergeron N, Strahan D, Ganschow P, Khanna A Cancer Control. 2022; 29:10732748221104666.

PMID: 35658635 PMC: 9174561. DOI: 10.1177/10732748221104666.